Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Immunol Res ; 2022: 2836128, 2022.
Article in English | MEDLINE | ID: mdl-35832651

ABSTRACT

The Huayu-Qiangshen-Tongbi (HQT) decoction, a Chinese medical formula, has been identified to show a potent therapeutic effect on rheumatoid arthritis (RA). However, the specific molecular mechanism of HQT in RA has not been well studied. In the present study, LPS-treated human rheumatoid fibroblast-like synoviocyte (FLS) MH7A cells and collagen-induced arthritis (CIA) mice were utilized as in vitro and in vivo models. Our results demonstrated that HQT could efficiently inhibit RA-induced inflammation by reducing the production of cytokines including tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1ß), and interleukin-6 (IL-6). Moreover, HQT significantly upregulated the expression of miR-125b. Besides, analysis of bioinformatics suggested casein kinase 2 (CK2) was a potential target of miR-125b. Luciferase reporter assay was performed and revealed that miR-125b suppressed CK2 expression in MH7A cells. Furthermore, miR-125b inhibited LPS-induced NF-kappa-B (NF-κB) activation, which is a downstream target of CK2. In addition, the NF-κB inhibitor ammonium pyrrolidinedithiocarbamate (PDTC) and NF-kappa-B inhibitor alpha (IkB-α) enhanced the inhibitory effect of miR-125b on the expression of TNF-α, IL-1ß, and IL-6. Taken together, our study revealed that HQT could attenuate RA through upregulating miR-125b to suppress NF-κB-induced inflammation by targeting CK2. The findings of this study should facilitate investigating the mechanism of HQT on RA and discovering novel therapeutic targets for RA.


Subject(s)
Arthritis, Rheumatoid , MicroRNAs , Synoviocytes , Animals , Arthritis, Rheumatoid/metabolism , Casein Kinase II/genetics , Casein Kinase II/metabolism , Casein Kinase II/pharmacology , China , Fibroblasts , Humans , Inflammation/metabolism , Interleukin-6/metabolism , Lipopolysaccharides/pharmacology , Mice , MicroRNAs/genetics , MicroRNAs/metabolism , NF-kappa B/metabolism , Synoviocytes/pathology , Tumor Necrosis Factor-alpha/metabolism
2.
Am J Chin Med ; 48(3): 535-558, 2020.
Article in English | MEDLINE | ID: mdl-32345031

ABSTRACT

The Th17/Treg axis plays a crucial role in immune-mediated inflammatory diseases (IMID) and might represent an interesting drug target of treatment strategy for these diseases. Accumulating evidence suggests a role for traditional Chinese medicine (TCM) in the modulation of Th17/Treg axis, but a comprehensive overview which summarizes this field hitherto is lacked. This paper performs a systematic literature review of the regulatory effects of TCM on the imbalance of Th17/Treg axis and its potential mechanisms. In addition, the frequency analysis and network pharmacology for the collected TCM herbs from clinical trial data were performed. The studies reported the changes in the ratio of Th17 and/or Treg cells as well as their transcription factor and related cytokines were included. Frequency analysis of composition of the 39 assessed TCM prescriptions showed that Astragalus membranaceus var.mongholicus (5.20%), Glycyrrhiza uralensis (3.67%), Paeonia obovate (3.06%), Salvia digitaloides (3.06%), and Angelica sinensis (2.75%) were the top five herbal components, which were closely associated to the treatment of IMID. Network pharmacology showed that six target proteins (transforming growth factor (TGF)-beta receptor type-1, TGF-beta receptor type-2, retineic-acid-receptor-related orphan nuclear receptor gamma (ROR-gamma), TGFB2, IL-17 and IL-2, respectively) might be involved in the regulatory effects of TCM on Th17/Treg axis. Moreover, there were nine active ingredients (including Oxymatrine, Baicalin, Triptolide, Paeoniflorin, Sinomenine, Celastrol, Emodin, Diosgenin and Chlorogenic acid) originating from TCM reported to have an immunological regulation effect on the Th17/Treg axis. The highlight of this systematic review is to reveal the pharmacological basis of TCM treating IMID and is helpful for supporting future pharmacologic-driven studies. Further research elucidates the immune-modulating mechanisms on Th17/Treg axis by TCM might provide a broader insight for the treatment of IMID.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Immune System Diseases/drug therapy , Immune System Diseases/immunology , Inflammation/drug therapy , Inflammation/immunology , Medicine, Chinese Traditional , Phytotherapy , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Angelica sinensis , Astragalus Plant , Drugs, Chinese Herbal/chemistry , Glycyrrhiza uralensis , Humans , Immune System Diseases/metabolism , Inflammation/metabolism , Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism , Paeonia , Receptor, Transforming Growth Factor-beta Type I/metabolism , Receptor, Transforming Growth Factor-beta Type II/metabolism , Salvia
3.
Phytomedicine ; 57: 403-410, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30851515

ABSTRACT

BACKGROUND: A combination of conventional disease-modifying anti-rheumatic drugs improves the treatment of rheumatoid arthritis but with high side-effects. Methotrexate (MTX) combination therapy that with high therapeutic efficacy and low toxicity is in demand in many countries to replace the use of expensive biological agents. STUDY DESIGN: This study was an open-label, 24-week, parallel randomized controlled trial conducted between November 2015 and December 2017. METHODS: Patients were randomly assigned at a 3:2 ratio to receive MTX combined with sinomenine (SIN) at a dose of 120 mg twice daily, or leflunomide (LEF) at a dose of 20 mg once daily. Efficacy and safety were assessed at weeks 4, 12 and 24. The primary efficacy endpoint was the proportion of patients achieving an American College of Rheumatology (ACR)50 response and a European League Against Rheumatism (EULAR) good response at week 24. RESULTS: A total of 101/120 (84.2%) patients completed 24 weeks of observation. In the intention-to-treat (ITT) analysis, 65.3% of patients treated with MTX + SIN showed improved disease activity as determined by the ACR50 response at week 24 compared to 69.6% of patients treated with MTX + LEF. A similar insignificant pattern was found for the ACR20 and ACR70 responses, as well as the clinical disease activity index, EULAR response, and remission and low disease activity rates between these two treatment groups. The per-protocol analysis showed results consistent with those of the ITT analysis. Notably, significant reductions in gastrointestinal adverse reactions and liver toxicity were found in patients treated with MTX + SIN compared to patients treated with MTX + LEF (p < 0.05). CONCLUSION: Considering the balance of efficacy and toxicity, the current study provides evidence that MTX + SIN combination therapy is probably one of the choices for treating patients with active rheumatoid arthritis in addition to MTX + LEF combination therapy.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Leflunomide/therapeutic use , Methotrexate/therapeutic use , Morphinans/therapeutic use , Adult , Antirheumatic Agents/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Drug Therapy, Combination , Female , Gastrointestinal Diseases/chemically induced , Humans , Leflunomide/adverse effects , Male , Methotrexate/adverse effects , Middle Aged , Morphinans/adverse effects , Treatment Outcome
4.
Exp Ther Med ; 15(6): 5221-5230, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29904406

ABSTRACT

Biqi capsule is a Traditional Chinese Medicine preparation for treating rheumatoid arthritis (RA), and clinical studies have indicatedthat its effect may be more beneficial than that of Western medicine. The present study aimed to estimate the efficacy and safety of Biqi capsule alone or combined with methotrexate (MTX) compared with MTX alone for treating RA by performing a meta-analysis of randomized controlled trials and controlled clinical trials. A systematic literature search of studies published until March 2017 was performed. References from relevant studies were screened to obtain additional articles. The results were independently evaluated for relevance, and full-text studies were assessed for eligibility. The risk of bias was assessed using the Cochrane collaboration tool for assessing risk of bias. Out of 558 citations that were initially retrieved, a total of 5 studies comprising 522 patients met the inclusion criteria. The risk of bias of these trials was generally unclear or high. Meta-analysis indicated that Biqi capsule had better effects on C-reactive protein [standardized mean difference (SMD), -7.05; 95% CI -(10.77-3.33)] and tender joint count [SMD, -3.02; 95% CI, -(3.81-2.22)] and fewer adverse effects (AEs) than MTX [relative risk (RR), 0.19; 95% CI, 0.08-0.43]. Biqi capsule plus MTX was superior to MTX in terms of the total effect (RR, 1.17; 95% CI, 1.06-1.28), rheumatoid factor [SMD, -12.54; 95% CI, -(16.87-8.20)], swollen joint count [SMD, -1.50; 95% CI, -(1.99-1.01)], score of joint swelling [SMD -2.07; 95% CI, -(2.76-1.38)], tender joint count [SMD, -2.16; 95% CI, -(2.86-1.47)] and score of joint tenderness [SMD, -4.69; 95% CI, -(5.92-3.47)]. There was no difference in AEs between Biqi capsule plus MTX and MTX (RR, 0.71; 95% CI, 0.34-1.50). In conclusion, the present study indicated that compared with MTX, Biqi capsule plus MTX appeared to have more benefits but that Biqi capsule alone was not better for RA patients than MTX. In the other words, Biqi capsule plus MTX is more effective and has fewer AEs compared to MTX. However, the trials selected in the present meta-analysis have various limitations, including the lack of blinding and the short duration of the treatment; therefore, the conclusions are not sufficiently definitive. More randomized controlled trials are necessary to evaluate the use of Biqi capsule for managing RA.

5.
Food Chem ; 249: 143-153, 2018 May 30.
Article in English | MEDLINE | ID: mdl-29407917

ABSTRACT

The use of coffee leaves as a novel beverage has recently received consumer interest, but there is little known about how processing methods affect the quality of final product. We applied tea (white, green, oolong and black tea) processing methods to process coffee leaves and then investigated their effects on phytochemical composition and related antioxidant and anti-inflammatory properties. Using Japanese-style green tea-processing of young leaves, and black tea-processing of mature (BTP-M) coffee leaves, produced contrasting effects on phenolic content, and associated antioxidant activity and nitric oxide (NO) inhibitory activity in IFN-γ and LPS induced Raw 264.7 cells. BTP-M coffee leaves also had significantly (P < .05) higher responses in NO, iNOS, COX-2, as well as a number of cytokines, in non-induced Raw 264.7. Our findings show that the age of coffee leaves and the type of processing method affect phytochemical profiles sufficiently to produce characteristic antioxidant and anti-inflammatory activities.


Subject(s)
Coffea/chemistry , Food Handling/methods , Phytochemicals/chemistry , Plant Extracts/chemistry , Plant Leaves/chemistry , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Antioxidants/chemistry , Antioxidants/pharmacology , Camellia sinensis/chemistry , Cell Survival/drug effects , Cytokines/immunology , Macrophages/drug effects , Macrophages/immunology , Mice , Nitric Oxide/immunology , Phenols/chemistry , Phenols/pharmacology , Phytochemicals/pharmacology , Plant Extracts/pharmacology , RAW 264.7 Cells , Tea/chemistry , Time Factors
6.
Chin J Integr Med ; 24(12): 891-896, 2018 Dec.
Article in English | MEDLINE | ID: mdl-28887810

ABSTRACT

OBJECTIVE: To analyze the effect of Chinese medicine (CM) on mortality and quality of life (QOL) of acquired immunodefificiency syndrome (AIDS) patients treated with combined antiretroviral therapy (cART). METHODS: A random sample of AIDS patients enrolled in the National Chinese Medicine Treatment Trial Program (NCMTP) that met the inclusion criteria was included in this study. NCMTP patients were included as the CM+cART group, and those not in the NCMTP were included as the cART group. Survival from September 2004 to September 2012 was analyzed by retrospective cohort study. QOL was analyzed by cross-sectional study. RESULTS: The retrospective cohort study included 528 AIDS patients, 322 in the CM+cART group and 206 in the cART group. After 8 years, the mortality in the CM+cART group was 3.3/100 person-years, which was lower than the cART group of 5.3/100 person-years (P<0.05). The hazard ratio (HR) for mortality in the cART group was 1.6 times that of the CM+cART group by Cox proportional hazard model analysis. After controlling for gender, age, marital status, education, and CD4+ T-cell count, the HR was 1.9 times higher in the cART group compared with the CM+cART group (P<0.05). The cross-sectional study investigated 275 AIDS patients. The mean scores of all QOL domains except spirituality/personal beliefs were higher in the CM+cART group than in the cART group (P<0.05). CONCLUSIONS: For AIDS patients, CM could help to prolong life, decrease mortality, and improve QOL. However, there were limitations in the study, so prospective studies should be carried out to confifirm our primary results.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Drugs, Chinese Herbal/therapeutic use , Rural Population , Acquired Immunodeficiency Syndrome/mortality , Adult , China/epidemiology , Female , Humans , Male , Quality of Life
7.
Food Chem Toxicol ; 105: 398-406, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28412402

ABSTRACT

Dry citrus peels, also known as "chenpi", have been traditionally used to treat and relieve intestinal inflammation. Recently we have reported that orange peel extracts (OPE) which contain relatively greater polymethoxylated flavone (PMF) content exhibit superior antioxidant and anti-inflammatory activities in vitro. Moreover, these bioactivities were notably greater than an equivalent flavonoid mixture (FM). The present study compares the effects of different OPE sources with distinct PMF composition on tight junction (TJ) dysfunction induced by ethanol. The OPE obtained from Xinhui, China, contained a 20-fold higher PMF content than extracts derived from the orange peels sourced from Guangxi. Xinhui-OPE treatment of ethanol treated Caco-2 cells corresponded to lower (P < 0.05) lactate dehydrogenase (LDH) leakage and higher (P < 0.05) glutathione reductase activity. Both OPE and the FM prevented ethanol-induced increases in Caco-2 cell paracellular permeability and the dislocation of TJ proteins, including claudin 4, occludin, and zonulin occludin-1 (ZO-1), respectively. Xinhui-OPE increased the expression of claudin 4 and occludin protein, but not mRNA, whereas, Guangxi-OPE and Xinhui-FM had no effect on TJ protein expression. In conclusion, OPE derived from sources that contain higher concentrations of PMF are more effective at preventing intestinal barrier dysfunction of TJ proteins induced by ethanol.


Subject(s)
Citrus sinensis/chemistry , Ethanol/adverse effects , Flavonoids/chemistry , Flavonoids/pharmacology , Fruit/chemistry , Plant Extracts/chemistry , Plant Extracts/pharmacology , Tight Junctions/drug effects , Caco-2 Cells , China , Claudin-4/genetics , Claudin-4/metabolism , Glutathione Reductase/genetics , Glutathione Reductase/metabolism , Humans , Intestinal Mucosa/metabolism , Intestines/cytology , Intestines/drug effects , Occludin/genetics , Occludin/metabolism , Tight Junctions/metabolism
8.
Food Chem ; 218: 15-21, 2017 Mar 01.
Article in English | MEDLINE | ID: mdl-27719891

ABSTRACT

Dried citrus peel derived from Citrus reticulata, also called "chenpi", possesses a complex mixture of flavonoids and has a history of traditional use to treat a variety of digestive disorders. We compared three sources of conventional chenpi from California (USA), Guangxi, Zhejiang, and two sources of "nchenpi", which contain greater nobiletin content, from Sichuan and Xinhui (China). Xinhui orange peel extract (OPE) had highest content of polymethoxylated flavones, along with greatest capacity to scavenge 2,2-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS), 2,2-diphenyl-1-pcrylhydrazyl (DPPH), and 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH) radicals and nitric oxide (NO). OPE also had higher NO, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) inhibitory activity than an equivalent mixture of flavonoids (P<0.05). In conclusion, nobiletin is a good chemical marker for assessing the anti-inflammatory potential of OPE from different sources. Obtaining "nchenpi" from either Sichuan or Xinhui provided potentially superior health benefits compared to conventional chenpi sources.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Citrus/chemistry , Flavonoids/pharmacology , Fruit/chemistry , Amidines/analysis , Animals , Anti-Inflammatory Agents/analysis , Antioxidants/analysis , Benzothiazoles/analysis , Biphenyl Compounds/analysis , California , Cell Survival/drug effects , China , Chromatography, High Pressure Liquid , Cyclooxygenase 2/metabolism , Cyclooxygenase 2 Inhibitors/analysis , Cyclooxygenase 2 Inhibitors/pharmacology , Drugs, Chinese Herbal/pharmacology , Flavones/analysis , Flavones/pharmacology , Flavonoids/analysis , Mice , Nitric Oxide/analysis , Nitric Oxide/antagonists & inhibitors , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/metabolism , Phenols/analysis , Phenols/pharmacology , Picrates/analysis , Plant Extracts/analysis , RAW 264.7 Cells , Sulfonic Acids/analysis
9.
Chin J Integr Med ; 23(5): 396-400, 2017 May.
Article in English | MEDLINE | ID: mdl-26142338

ABSTRACT

Moxibustion is an ancient therapeutic technique used in Chinese medicine. Governor Vessel moxibustion (GVM) was developed from long snake moxibustion, a popular technique used in China's Jiangsu and Zhejiang Provinces, and is significantly more effective than general moxibustion. We aimed to review GVM, including its theoretical basis, choices of moxibustion points and materials, operation procedures, clinical applications, and contraindications. This information could increase the appropriate use of GVM and support further in-depth research.


Subject(s)
Medicine, Chinese Traditional , Moxibustion , Fatigue/etiology , Humans , Renal Dialysis/adverse effects
10.
Oncotarget ; 7(2): 1193-202, 2016 Jan 12.
Article in English | MEDLINE | ID: mdl-26498361

ABSTRACT

OBJECTIVES: This review stated the possible application of the active components of licorice, glycyrrhizin (GL) and glycyrrhetinic acid (GA), in rheumatoid arthritis (RA) treatment based on the cyclooxygenase (COX)-2/thromboxane A2 (TxA2) pathway. METHODS: The extensive literature from inception to July 2015 was searched in PubMed central, and relevant reports were identified according to the purpose of this study. RESULTS: The active components of licorice GL and GA exert the potential anti-inflammatory effects through, at least in part, suppressing COX-2 and its downstream product TxA2. Additionally, the COX-2/TxA2 pathway, an auto-regulatory feedback loop, has been recently found to be a crucial mechanism underlying the pathogenesis of RA. However, TxA2 is neither the pharmacological target of non-steroidal anti-inflammatory drugs (NSAIDs) nor the target of disease modifying anti-rheumatic drugs (DMARDs), and the limitations and side effects of those drugs may be, at least in part, attributable to lack of the effects on the COX-2/TxA2 pathway. Therefore, GL and GA capable of targeting this pathway hold the potential as a novel add-on therapy in therapeutic strategy, which is supported by several bench experiments. CONCLUSIONS: The active components of licorice, GL and GA, could not only potentiate the therapeutic effects but also decrease the adverse effects of NSAIDs or DMARDs through suppressing the COX-2/TxA2 pathway during treatment course of RA.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Glycyrrhetinic Acid/therapeutic use , Glycyrrhiza/chemistry , Glycyrrhizic Acid/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/metabolism , Cyclooxygenase 2/metabolism , Humans , Phytotherapy/methods , Thromboxane A2/metabolism , Treatment Outcome
11.
Article in English | MEDLINE | ID: mdl-26379753

ABSTRACT

Chinese medicines are gaining wider acceptance. They have been used for treating rheumatoid arthritis (RA) for thousands of years, and the need to investigate the interaction between Chinese medicines and western medicines is widely recognized. In this study, a large number of RCTs and CCTs were analyzed to systematically assess the effects and adverse events of Zhengqing Fengtongning (ZQFTN) for RA. Eleven studies that contained 956 participants (508 in the treatment group; 448 in the control group) were included. The results showed that although ZQFTN combined with methotrexate MTX could not decrease the swollen joint count and tender joint count of RA patients better than MTX alone, the combination therapy might relieve the duration of morning stiffness (SMD: -16.06; 95% CI: -28.77 to -3.34), reduce laboratory indexes (RF: SMD: -10.84; 95% CI: -19.39 to -2.29; ESR: SMD: -7.26; 95% CI: -11.54 to -2.99; CRP: SMD: -3.66; 95% CI: -5.94 to -1.38), and improve the overall effect (RR: 1.08; CI: 1.01 to 1.16) better than monotherapy. The combination therapy was significantly better in controlling adverse drug reactions (RR: 0.60; 95% CI: 0.46 to 0.79). Through this systematic review, we found that ZQFTN combined with MTX for the treatment of RA might have better clinical efficacy than MTX only and might be superior in terms of controlling adverse drug reactions.

12.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 35(11): 1326-30, 2015 Nov.
Article in Chinese | MEDLINE | ID: mdl-26775479

ABSTRACT

OBJECTIVE: To evaluate the clinical efficacy and safety of Huayu Tongbi Recipe (HTR) combined methotrexate (MTX) in treating refractory rheumatoid arthritis (RRA). METHODS: Totally 167 RRA patients were assigned to the treatment group (73 cases) and the control group (94 cases) according to different therapeutic methods. Patients in the treatment group were treated with HTR combined MTX, while those in the control group were treated with leflunomide (LEF) combined MTX. Clinical signs and symptoms, RF, CRP, ESR, disease activity score 28 (DAS28), and safety indicators were compared between the two groups before treatment, at week 12 and 24 after treatment. The efficacy and safety indices were also evaluated. RESULTS: At week 12 after treatment the total effective rate was 82.2% (60/73 cases) in the treatment group and 79.8% (75/94 cases) in the control group, showing no statistical difference between the two groups (chi2 = 0.15, P > 0.05). At week 24 after treatment the total effective rate was 78.1% (57/73 cases) in the treatment group and 755% (71/94 cases) in the control group, showing no statistical difference between the two groups (chi2 = 0.15, P > 0.05). There was statistical difference in the total effective rate between week 24 and week 12 in the control group (chi2 = 0.49, P < 0.05). Clinical signs and symptoms, RF, CRP, ESR, and DAS28 were significantly improved in the two groups after 12- and 24-week treatment (P < 0.01). There was no statistical difference in the improvement at week 12 after treatment between the two groups (P > 0.05). There was statistical difference in time of morning stiffness, tender joint numbers, swollen joint numbers, patient global assessment, RF, CRP, and DAS28 at week 24 after treatment between the two groups (P < 0.05). Besides, adverse reactions occurred less in the treatment group than in the control group (P < 0.01). CONCLUSION: The efficacy of HTR combined MTX was equivalent to that of LEF (10 mg per day) combined MTX, but with more stable therapeutic effects and less adverse reactions.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Drugs, Chinese Herbal/therapeutic use , Methotrexate/therapeutic use , Antirheumatic Agents/pharmacology , Arthralgia , Drug Therapy, Combination , Drugs, Chinese Herbal/pharmacology , Humans , Isoxazoles , Leflunomide , Methotrexate/pharmacology , Phytotherapy , Treatment Outcome
13.
Fitoterapia ; 92: 61-71, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24125915

ABSTRACT

Eubacterium limosum ZL-II is an anaerobic bacterium with demethylated activity, which was isolated from human intestinal bacteria in our previous work. In this study, the flavonolignan constituents of Silybi Fructus were biotransformed by E. limosum(1) ZL-II, producing four new transformation products - demethylisosilybin B (T1), demethylisosilybin A (T2), demethylsilybin B (T3) and demethylsilybin A (T4), among which T1 and T2 were new compounds. Their chemical structures were identified by ESI-TOF/MS, (1)H NMR, (13)C NMR, HMBC and CD spectroscopic data. The bioassay results showed that the transformation products T1-T4 exhibited significant inhibitory activities on Alzheimer's amyloid-ß 42 (Aß42(2)) aggregation with IC50 values at 7.49 µM-10.46 µM, which were comparable with that of the positive control (epigallocatechin gallate, EGCG(3), at 9.01 µM) and much lower than those of their parent compounds (at not less than 145.10 µM). The method of biotransformation by E. limosum ZL-II explored a way to develop the new and active lead compounds in Alzheimer's disease from Silybi Fructus. However, the transformation products T1-T4 exhibited decreased inhibitory activities against human tumor cell lines comparing with their parent compounds.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/antagonists & inhibitors , Eubacterium/metabolism , Flavonolignans/pharmacology , Intestines/microbiology , Peptide Fragments/antagonists & inhibitors , Plant Extracts/pharmacology , Silybum marianum/chemistry , Alzheimer Disease/drug therapy , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/metabolism , Antineoplastic Agents, Phytogenic/pharmacology , Biotransformation , Flavonolignans/chemistry , Flavonolignans/metabolism , Fruit , HeLa Cells , Humans , Intestinal Mucosa/metabolism , Silybum marianum/microbiology , Molecular Structure , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/metabolism
14.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 32(6): 751-3, 2012 Jun.
Article in Chinese | MEDLINE | ID: mdl-22978094

ABSTRACT

OBJECTIVE: To investigate the main features of Chinese medicine (CM) syndromes and differences of hematotoxicity reaction induced by highly active antiretroviral therapy. METHODS: The information of CM four diagnostic methods was collected by cross-sectional study. Their syndrome features were summed up and their differences were analyzed. RESULTS: Of the 216 patients, the main syndromes were qi-blood deficiency syndrome (142 cases, accounting for 65.7%) and Pi-Shen yang deficiency syndrome (74 cases, accounting for 34.3%). The score of qi-blood deficiency syndrome was obviously lower than that of Pi-Shen yang deficiency syndrome (P < 0.05). The count of CD4+ T cells was higher in qi-blood deficiency syndrome than in Pi-Shen yang deficiency syndrome. There was no statistical difference in the serum viral load between the two groups (P > 0.05). The quality of life was higher in qi-blood deficiency syndrome than in Pi-Shen yang deficiency syndrome, but with no statistical difference (P > 0.05). CONCLUSIONS: Qi-blood deficiency syndrome and Pi-Shen yang deficiency syndrome were main syndromes of hematotoxicity reaction induced by HAART. The pathogenic condition of qi-blood deficiency syndrome patients was milder. There was no obvious difference in the quality of life, CD4+ T cells, and the viral loads between two syndromes.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Antiretroviral Therapy, Highly Active/adverse effects , Medicine, Chinese Traditional , Adult , CD4 Lymphocyte Count , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Quality of Life , Viral Load , Yang Deficiency/diagnosis , Yin Deficiency/diagnosis
15.
J Food Sci ; 75(7): C613-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21535527

ABSTRACT

UNLABELLED: High hydrostatic pressure (HHP) technology was applied to organic Echinacea purpurea (E. purpurea) roots and flowers to determine the feasibility of using this technology for cold herb pasteurization, to produce microbiologically safe and shelf-stable products for the natural health products (NHPs) industry. HHP significantly (P < 0.01) reduced microbial contamination in both roots and flowers without affecting the phytochemical retention of chicoric and chlorogenic acids, and total alkamide contents. The antioxidant activity of E. purpurea methanol-derived extracts, evaluated in both chemical (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) [ABTS] and oxygen radical absorption capacity [ORAC] assay) and in cell culture models (RAW264, 7 macrophage, H(2)O(2)-induced intracellular oxidation, and lipopolysaccharide [LPS]-induced nitric oxide production), was not adversely affected by the application of HHP at both 2 and 5 min at 600 mPa. Furthermore, HHP did not affect the capacity of E. purpurea extracts to suppress nitric oxide production in LPS-activated macrophage cells. Therefore, our results show that HHP is an effective pasteurization process treatment to reduce microbial-contamination load while not adversely altering chemical and bioactive function of active constituents present in organic E. purpurea. PRACTICAL APPLICATION: Our study reports for the first time, the effectiveness of using high hydrostatic pressure (HHP) technology pressure to pasteurize E. purpurea root and flower, and the comparative retention of bioactive phytochemicals. Therefore, this technique can be used in food and natural health product industries to produce high-quality, microbiologically safe, and shelf-stable products.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/pharmacology , Dietary Supplements/analysis , Disinfection/methods , Echinacea/microbiology , Plant Extracts/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/analysis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Antioxidants/analysis , Antioxidants/chemistry , Bacterial Load , Caffeic Acids/analysis , Cell Line, Transformed , Chlorogenic Acid/analysis , Dietary Supplements/microbiology , Echinacea/chemistry , Escherichia coli/growth & development , Feasibility Studies , Flowers/chemistry , Flowers/microbiology , Hydrostatic Pressure , Macrophages/drug effects , Macrophages/metabolism , Mice , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Plant Extracts/chemistry , Plant Roots/chemistry , Plant Roots/microbiology , Succinates/analysis
SELECTION OF CITATIONS
SEARCH DETAIL